News
UCBJY
119.32
+1.98%
2.32
Barclays Remains a Hold on UCB SA (0NZT)
TipRanks · 3d ago
Weekly Report: what happened at UCBJY last week (0831-0904)?
Weekly Report · 4d ago
Trump unveils new drug-pricing accords with CSL, Astellas, and other biotech drugmakers
Seeking Alpha · 09/01 04:10
Weekly Report: what happened at UCBJY last week (0824-0828)?
Weekly Report · 08/31 10:34
Weekly Report: what happened at UCBJY last week (0817-0821)?
Weekly Report · 08/24 10:35
Weekly Report: what happened at UCBJY last week (0810-0814)?
Weekly Report · 08/17 10:36
Weekly Report: what happened at UCBJY last week (0803-0807)?
Weekly Report · 08/10 10:30
TD Cowen Reaffirms Their Buy Rating on UCB SA (0NZT)
TipRanks · 08/04 08:57
UBS Sticks to Its Buy Rating for UCB SA (0NZT)
TipRanks · 08/04 08:56
UCB S.A. Earnings Call Signals Robust Growth
TipRanks · 08/04 00:10
AstraZeneca tops pharma growth rankings while Bristol Myers trails amid merger talks
Seeking Alpha · 08/03 12:11
Weekly Report: what happened at UCBJY last week (0727-0731)?
Weekly Report · 08/03 10:30
Stacy Ku Initiates Buy on UCB, Citing Attractive Valuation and Early Bimzelx-Driven Growth Inflection
TipRanks · 08/03 08:55
UCB upgraded to Hold from Underperform at Jefferies
TipRanks · 08/03 08:20
Barclays Sticks to Their Hold Rating for UCB SA (0NZT)
TipRanks · 08/03 07:15
Hold Rating Maintained as De-Rated Valuation Balances Risk-Reward; Price Target Raised from $212 to $220 on Improved EBITDA Outlook Amid Ongoing Bimzelx Concerns
TipRanks · 08/03 06:05
UCB SA (0NZT) Receives a Buy from Goldman Sachs
TipRanks · 08/03 05:35
UCB SA Non-GAAP EPS of €6.84, revenue of €4.27B; updates FY2026 outlook
Seeking Alpha · 07/30 07:14
Weekly Report: what happened at UCBJY last week (0720-0724)?
Weekly Report · 07/27 10:35
Weekly Report: what happened at UCBJY last week (0713-0717)?
Weekly Report · 07/20 10:30
More
Webull provides a variety of real-time UCBJY stock news. You can receive the latest news about Ucb S A through multiple platforms. This information may help you make smarter investment decisions.
About UCBJY
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.